Patents Assigned to Pharmexa A/s
-
Publication number: 20090092579Abstract: Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (A?). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A? which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of A?'s B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination.Type: ApplicationFiled: April 23, 2008Publication date: April 9, 2009Applicant: Pharmexa A/SInventors: Martin Roland Jensen, Peter Birk, Klaus Gregorius Nielsen
-
Publication number: 20080253993Abstract: Disclosed is a method for inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) in humans. The method comprises effecting uptake by antigen presenting cells of epitopes (preferably all) from the extracellular portion of human EGFR and of at least one non-human T helper epitope (TH epitope) so as to induce antibodies against EGFR. Immunization may be accomplished by protein vaccination, nucleic acid vaccination and live or viral vaccination. The immune response is useful in treatment of malignancies. Also disclosed are modified EGFR proteins and expression plasmids useful for the immunization method as well as recombinant gene technology tools such as nucleic acids, vectors and host cells.Type: ApplicationFiled: March 30, 2006Publication date: October 16, 2008Applicant: Pharmexa A/SInventors: Lucilla Steinaa, Valery Renard
-
Patent number: 7285273Abstract: Improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases are disclosed. A method is provided for down-regulating interleukin 5 (IL5) by enabling the production of antibodies against IL5 thereby reducing the level of activity of eosinophils.Type: GrantFiled: April 19, 2000Date of Patent: October 23, 2007Assignee: Pharmexa A/SInventor: Steen Klysner
-
Publication number: 20070184023Abstract: The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in molecular biology that assist in the provision of the immunogenic variants.Type: ApplicationFiled: October 28, 2004Publication date: August 9, 2007Applicant: Pharmexa A/SInventors: Peter Rasmussen, Florence Dal Degan, Valery Renard, Steen Klysner, Birgitte Volck
-
Patent number: 7135181Abstract: A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.Type: GrantFiled: February 20, 2001Date of Patent: November 14, 2006Assignee: Pharmexa A/SInventors: Martin Roland Jensen, Peter Birk Rasmussen, Klaus Gregorius Nielsen
-
Publication number: 20060240511Abstract: The present invention provides for a novel method for purification of EGFR family proteins obtained from cultures of insect cells. The process comprises subsequent steps of a) diafiltration and exchange of culture medium with buffer, b) immobilized metal affinity chromatography (IMAC), c) size exclusion chromatography (SEC), and d) anion exchange chromatography (AIE). The method also provides for an immunogenic variant of HER-2 protein which for which the purification process has been especially adapted, as well as means for the preparation of the variant.Type: ApplicationFiled: June 24, 2004Publication date: October 26, 2006Applicant: PHARMEXA A/SInventors: Marie Eskling, Klaus Nielsen
-
Patent number: 7118750Abstract: A modified human TNF? molecule is capable of raising neutralizing antibodies towards unmodified human TNF? following administration of the modified TNF? to a human host, wherein one or more peptide fragments of the human TNF? molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNF?-molecule containing at least one TNF? B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front ?-sheet, in any one of the connecting loops, or in any one of the B?, I, or D strands of the back ?-sheet.Type: GrantFiled: April 15, 1998Date of Patent: October 10, 2006Assignee: Pharmexa A/SInventors: Martin Roland Jensen, Søren Mouritsen, Henrik Elsner, Iben Dalum
-
Patent number: 7097837Abstract: The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunization and a method for identification of suitable immunogens of the invention.Type: GrantFiled: February 19, 2002Date of Patent: August 29, 2006Assignee: Pharmexa A/SInventors: Klaus Gregorius Nielsen, Peter Koefoed
-
Patent number: 7070784Abstract: Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.Type: GrantFiled: July 20, 2000Date of Patent: July 4, 2006Assignee: Pharmexa A/SInventors: Torben Halkier, Søren Mouritsen, Steen Klysner
-
Patent number: 7056512Abstract: Disclosed are novel methods for increasing muscle mass by means of immunization against Growth Differentiation Factor 8 (GDF-8, myostatin). Immunization is preferably effected by administration of analogues of GDF-8 which are capable of inducing antibody production against homologous GDF-8. Especially preferred as an immunogen is homologous GDF-8 which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the tertiary structure of the homologous GDF-8. Also disclosed are nucleic acid vaccination against GDF-8 and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic GDF-8 analogues, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.Type: GrantFiled: July 20, 2000Date of Patent: June 6, 2006Assignee: Pharmexa A/SInventors: Steen Klysner, Soren Mouritsen, Torben Halkier
-
Patent number: 7005498Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: GrantFiled: October 5, 1999Date of Patent: February 28, 2006Assignee: Pharmexa A/sInventors: Lucilla Steinaa, Søren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Gregorius Nielsen, Gunilla Karlsson, Peter Birk Rasmussen
-
Publication number: 20060008465Abstract: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.Type: ApplicationFiled: August 11, 2005Publication date: January 12, 2006Applicant: PHARMEXA A/SInventors: Lucilla Steinaa, Soren Mouritsen, Anand Gautam, Iben Dalum, Jesper Hanning, Dana Leach, Klaus Nielsen, Gunilla Karlsson, Peter Rasmussen
-
Patent number: 6746669Abstract: The present invention relates to improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases. A method is provided for down-regulating interleukin 5 (IL5) by enabling the production of antibodies against IL5 thereby reducing the level of activity of eosinophils. The invention also provides for methods of producing modified IL5 useful in this method as well as for the modified IL5 as such. Also encompassed by the present invention are nucleic acid fragments encoding modified IL5 as well as vectors incorporating these nucleic acid fragments and host cells and cell lines transformed therewith. The invention also provides for a method for the identification of IL5 analogues which are useful in the method of the invention as well as for compositions comprising modified IL5 or comprising nucleic acids encoding the IL5 analogues.Type: GrantFiled: April 21, 2000Date of Patent: June 8, 2004Assignee: Pharmexa A/SInventor: Steen Klysner
-
Publication number: 20030082514Abstract: Biologically active peptides and nucleic acids are identified by a method comprising the following steps: (a) production of a pool of appropriate vectors each containing totally or partly random DNA sequences, (b) efficient transduction of said vectors into a number of identical eukaryotic cells in such a way that a single ribonucleic acid and possibly peptide is expressed or a limited number of different random ribonucleic acids and peptides are expressed by each cell, (c) screening of said transduced cells to see whether some of them have changed a certain phenotypic trait, (d) selection and cloning of said changed cells, (e) isolation and sequencing of the vector DNA in said phenotypically changed cells, and (f) deducing the ribonucleic acid and peptide sequences from the DNA sequence. The peptide sequences may be introduced into or fused to a larger protein, preferably an antibody molecule or a fragment thereof.Type: ApplicationFiled: June 20, 2002Publication date: May 1, 2003Applicant: Pharmexa A/SInventors: Martin Roland Jensen, Finn Skou Pedersen, Soren Mouritsen, Peter Hindersson, Mogens Duch, Michael Schandorf Sorensen, Iben Dalum, Anders Henrik Lund
-
Publication number: 20020172673Abstract: The present invention discloses methods for immunizing against autologous (self) Immunoglobulin E (IgE). In particular, the invention discloses methods for inducing cytotoxic T-lymphocytes that will specifically down-regulate B-cells producing autologous IgE, notably by means of nucleic acid vaccination or live vaccination. Also disclosed are methods for inducing antibodies reactive with autologous IgE as well as methods for inducing a combined antibody and CTK response specific for IgE. The invention also discloses specific immunogenic protein constructs, nucleic acids encoding these as well as various formulations and tools for preparing the vaccines, including vectors and transformed host cells.Type: ApplicationFiled: September 6, 2001Publication date: November 21, 2002Applicant: Pharmexa A/SInventors: Steen Klysner, Paul von Hoegen, Bjorn Voldborg, Anand Gautam